Search Results

You are looking at 1 - 10 of 26 items for :

  • "lobular carcinoma in situ" x
Clear All
Full access

Arvind Bambhroliya, Mariana Chavez-MacGregor and Abenaa M. Brewster

Breast Cancer Prevention Trial (BCPT) enrolled women based on either age of 60 years or older, or age 35 to 59 years with a modified Gail model 5-year predicted risk of breast cancer of 1.66% or greater or a history of lobular carcinoma in situ (LCIS

Full access

Sarah Asad, Carlos H. Barcenas, Richard J. Bleicher, Adam L. Cohen, Sara H. Javid, Ellis G. Levine, Nancy U. Lin, Beverly Moy, Joyce Niland, Antonio C. Wolff, Michael J. Hassett and Daniel G. Stover

at diagnosis compared with those who did not have rrTNBC (supplemental eTable 2). Figure 1. CONSORT diagram. Abbreviations: DCIS, ductal carcinoma in situ; HER2+, HER2-positive; HR+, hormone receptor–positive; LCIS, lobular carcinoma in situ; rrTNBC

Full access

Amy Ly, Jill C. Ono, Kevin S. Hughes, Martha B. Pitman and Ronald Balassanian

, fine-needle aspiration biopsy; IBC, invasive breast carcinoma; LCIS, lobular carcinoma in situ; MGH, Massachusetts General Hospital. diagnosis turnaround times were similar for FNAB and core biopsy specimens, averaging 3 to 4 days. Overall

Full access

Benjamin O. Anderson, Kristine E. Calhoun and Eric L. Rosen

situ: a rare form of mammary carcinoma . Am J Pathol 1941 ; 17 : 491 – 496 . 2. Carson W Sanchez-Forgach E Stomper P . Lobular carcinoma in situ: observation without surgery as an appropriate therapy . Ann Surg Oncol 1994 ; 1 : 141

Full access

Christos Vaklavas, John R. Ross, Lisle M. Nabell, Andres Forero, Martin J. Heslin and Tina E. Wood

suspicious enhancement was found on MRI of the right breast. On pathology, this lesion was consistent with infiltrating mammary carcinoma with predominantly lobular features and lobular carcinoma in situ ( Figure 2 ). The specimen was positive for estrogen

Full access

Parijatham S. Thomas

benign disease. 1 However, not all benign breast biopsies are equal, and certain lesions confer an increased risk for breast cancer. Specifically, lesions with atypical hyperplasia (AH) and lobular carcinoma in situ (LCIS) have been shown to be

Full access

Heidi Ko, Yaser Baghdadi, Charito Love and Joseph A. Sparano

. Electronic medical records were reviewed and the following exclusion criteria were applied: patients with stage IV disease, ductal carcinoma in situ, lobular carcinoma in situ, or stage I disease before PET/CT; treatments before PET/CT; and no adequate

Full access

Constance D. Lehman and Robert A. Smith

MRI among women in the Memorial Sloan Kettering (MSK) Special Surveillance Breast Program who had biopsy confirmed atypia or lobular carcinoma in situ (LCIS), and concluded that MRI offered a small added benefit in patients with a prior diagnosis of

Full access

Susan Lester

in situ component may be overgrown by the invasive carcinoma. The 20% to 30% of cases of breast cancer detected as CIS (predominantly ductal carcinoma in situ [DCIS], with fewer women with lobular carcinoma in situ [LCIS]) are likely to have

Full access

Therese B. Bevers, Deborah K. Armstrong, Banu Arun, Robert W. Carlson, Kenneth H. Cowan, Mary B. Daly, Irvin Fleming, Judy E. Garber, Mary Gemignani, William J. Gradishar, Helen Krontiras, Swati Kulkarni, Christine Laronga, Loretta Loftus, Deborah J. MacDonald, Martin C. Mahoney, Sofia D. Merajver, Ingrid Meszoely, Lisa Newman, Elizabeth Pritchard, Victoria Seewaldt, Rena V. Sellin, Charles L. Shapiro and John H. Ward

Hodgkin disease], hormone replacement therapy [HRT], alcohol consumption); and other factors (e.g., number of breast biopsies, atypical hyperplasia or lobular carcinoma in situ [LCIS], breast density, body mass index). Estimating breast cancer risk for